Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Hibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka, Masayuki Takeda, Shintaro Kanda, Keisuke Kirita, Shunsuke Teraoka, Kazuhiko Nakagawa, Yutaka Fujiwara, I. Yasuda, Sumiko Okubo, Masayuki Shintani, Matthew P. Kosloski, Charity Scripture, Tomohide Tamura, I. Okamoto

研究成果: Contribution to journalArticle

4 引用 (Scopus)

抜粋

Objectives: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) on small cell lung cancer (SCLC) tumors, is internalized and releases the toxin pyrrolobenzodiazepine to induce cell death. This open label phase I study was the first study of Rova-T in Japanese patients. The aim of this study was to evaluate, safety, pharmacokinetics, and preliminary efficacy of Rova-T in Japanese patients with advanced recurrent SCLC. Materials and methods: Patients received Rova-T (0.2 or 0.3 mg/kg) by intravenous infusion on Day (D) 1 of each 6-week cycle for 2 doses and dexamethasone (8 mg BID oral) on D-1, D1, and D2 of each 6-week cycle. Retreatment with Rova-T was permitted for patients who tolerated their initial doses and then progressed after disease control (defined as stable disease or better) was observed for at least 12 weeks after their last dose of Rova-T. Results: Rova-T exhibited toxicity that was generally manageable in Japanese patients (N = 29). No dose-limiting toxicities were experienced. The most common treatment-related adverse events (≥25% of patients, all grades) were platelet count decreased, pleural effusion, peripheral edema, aspartate aminotransferase increased, white blood cell count decreased, neutrophil count decreased, alanine aminotransferase increased, hypoalbuminaemia, anemia and decreased appetite. Safety and pharmacokinetics exposures were similar to previous observations in non-Japanese populations. Per investigator assessment of DLL3 high patients, 17% (3/18) had confirmed partial responses, and the disease control rate was 56%, mPFS was 2.9 months, and mOS was 7.4 months. Conclusions: These preliminary data support further exploration of Rova-T treatment in Japanese patients with SCLC in global studies. This trial was registered with ClinicalTrials.gov as NCT03086239.

元の言語英語
ページ(範囲)145-150
ページ数6
ジャーナルLung Cancer
135
DOI
出版物ステータス出版済み - 9 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

フィンガープリント Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Udagawa, H., Akamatsu, H., Tanaka, K., Takeda, M., Kanda, S., Kirita, K., Teraoka, S., Nakagawa, K., Fujiwara, Y., Yasuda, I., Okubo, S., Shintani, M., Kosloski, M. P., Scripture, C., Tamura, T., & Okamoto, I. (2019). Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung Cancer, 135, 145-150. https://doi.org/10.1016/j.lungcan.2019.07.025